Frank, Markus H.
- Brigham and Women's Hospital · Dermatology (topic-inferred)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #2,305
- Program Leader
- R01 Holder
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2002 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2.6M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#2,305
By linked amount among FY2023 PIs
Earliest Year Loaded
2002
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Frank, Markus H. as a PI. Multi-PI records show the full award amount for context.
- 5P01AG071463-02P01Contact PIMulticomponent Therapy for Age-related Skin Stem Cell DeficiencyBrigham and Women's Hospital · Dermatology (topic-inferred)$2.2Maward amount
- 5R01HL161087-02R01Contact PISkin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHDBrigham and Women's Hospital · Dermatology (topic-inferred)$413.8Kaward amount
Award organization
Organizations that administered FY2023 awards listing Frank, Markus H. as a PI.
FY2023 award administered by Brigham and Women's Hospital (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2002First NIH AwardBrigham and Women's Hospital
- 2018$500K Cumulative Funding
- 2018$1M Cumulative Funding
- 2018Entered Top 50% NationallyRanked #5886
- 2018R01 Grant Holder
- 2019$2M Cumulative Funding
- 2019Program/Center Grant Leader
- 2020Entered Top 25% NationallyRanked #2206
- 2021$5M Cumulative Funding
- 2022Entered Top 10% NationallyRanked #1090
- 2023$10M Cumulative Funding